original ) (raw )Common allelic variants of the farnesyl diphosphate synthase gene influence the response of osteoporotic women to bisphosphonates
Jose Riancho
The Pharmacogenomics Journal, 2012
View PDFchevron_right
Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis
Alena Rudenka
PLOS ONE, 2019
View PDFchevron_right
Pharmacogenomics of Osteoporosis
Luigi Gennari
Clinical Reviews in Bone and Mineral Metabolism, 2010
View PDFchevron_right
Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women
Sergio Crovella
Inflammopharmacology, 2017
View PDFchevron_right
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
M. Qari
Pharmacogenomics and Personalized Medicine, 2009
View PDFchevron_right
Pharmacogenetics of osteoporosis and the prospect of individualized prognosis and individualized therapy
Jacqueline Center
2008
View PDFchevron_right
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw
Yan Gong
International journal of oral and maxillofacial surgery, 2011
View PDFchevron_right
Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms
Luigi Gennari
The Journal of Steroid Biochemistry and Molecular Biology, 2002
View PDFchevron_right
Genomewide Pharmacogenetics of Bisphosphonate-Induced Osteonecrosis of the Jaw: The Role of RBMS3
A. Floratos
The Oncologist, 2012
View PDFchevron_right
Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: a case control study
Grace Juyun Kim
Journal of Translational Medicine, 2019
View PDFchevron_right
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy
N. Henry , James Rae
British Journal of Cancer, 2010
View PDFchevron_right
Personalized medicine approach to osteoporosis management in women: integrating genetics, pharmacogenomics, and precision treatments
John Imaralu
Clinical Research Communications
View PDFchevron_right
The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women
Ramona Babosova
BMC Medical Genetics, 2018
View PDFchevron_right
Gene Network of Susceptibility to Atypical Femoral Fractures Related to Bisphosphonate Treatment
Susana Balcells
Genes
View PDFchevron_right
CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post-menopausal women to hormonal replacement therapy
Caterina Fossi
Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases, 2014
View PDFchevron_right
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial
Gaetano Lombardi
Osteoporosis International, 2005
View PDFchevron_right
Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
wirawan adikusuma
Disease Markers, 2020
View PDFchevron_right
Single nucleotide polymorphisms in new candidate genes are associated with bone mineral density and fracture risk
Zsolt Nagy
European Journal of Endocrinology, 2008
View PDFchevron_right
A reappraisal of generic bisphosphonates in osteoporosis
Jonathan Adachi
Osteoporosis International, 2012
View PDFchevron_right
The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density
tusar giri
Bone, 2009
View PDFchevron_right
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw
Loredana Cavalli
2011
View PDFchevron_right
Gene polymorphisms and osteoporotic fractures: A study in postmenopausal French women
Jean Testa
Joint Bone Spine, 2009
View PDFchevron_right
Response to bisphosphonate is not impaired during prolonged treatment of women with osteoporosis
Neveen Hamdy
Bone, 2011
View PDFchevron_right
Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females
Ahmad Azam Malik
PLOS ONE
View PDFchevron_right
[Genetic polymorphism of estrogen receptor alpha--a risk factor of osteoporosis?]
Joanna Bartkowiak-Wieczorek
Ginekologia polska, 2006
View PDFchevron_right
Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density
Nicola Napoli
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2005
View PDFchevron_right
Concerns on Medications Used in Osteoporosis
Julie Li-Yu
Journal of Clinical Rheumatology and Immunology
View PDFchevron_right
Osteoporosis genetics: year 2011 in review
Miri Zinder
BoneKEy Reports, 2012
View PDFchevron_right
Bisphosphonates for the treatment of osteoporosis: insights for clinicians
ALIYA KHAN
Therapeutic Advances in Chronic Disease, 2010
View PDFchevron_right
Analysis of Three Functional Polymorphisms in Relation to Osteoporosis Phenotypes: Replication in a Spanish Cohort
Natàlia García-giralt
Calcified Tissue International, 2010
View PDFchevron_right
Vitamin D Receptor Gene Polymorphisms Affect Osteoporosis-Related Traits and Response to Antiresorptive Therapy
vladimira krajcovicova
Genes
View PDFchevron_right
CYP19A1 Genetic Polymorphisms rs4646 and Osteoporosis in Patients Treated with Aromatase Inhibitor-Based Adjuvant Therapy
Marina Borro
The Eurasian Journal of Medicine, 2015
View PDFchevron_right
Polymorphisms of the farnesyl diphosphate synthase gene modulate bone changes in response to atorvastatin
María Zarrabeitia , Jose Riancho
Rheumatology International, 2013
View PDFchevron_right